Schedule 13G ownership disclosure
LYELL IMMUNOPHARMA INC
Security class unavailable · CUSIP: 55083R104
Event date: 2024-10-25
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 8,325,000
- Percent of class
- 3.2000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-24-113135
- Form type
- SC 13G
- Filer
- Foresite Capital Fund IV, L.P.
- CIK
- CIK 1704131
- Filed
- Oct 31, 2024
- Reporting period
- Oct 25, 2024
- Description
- Schedule 13G beneficial ownership